SEC INSIDER TRANSACTIONS
METLIFE INC (MET) Insider Transactions
Explore official ownership filings, with every record linked to its source.
MET · METLIFE INC
How to read this data ↗
Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 1 filings · fetched 2026-11-13T18:57:13Z
View six-calendar-month insider history →
Recent reported activity
Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.
| Transaction / filed | Reporting owner(s) | Code / security | Quantity | Price as filed | Ownership | Source |
|---|---|---|---|---|---|---|
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F7 | M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 94,578D | 0 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F6 | M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 90,726D | 0 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F5 | M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,608D | 0 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F3, F4 | M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 28,817D | 0 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 187,425D | 102.9676 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: | M Exercise / conversionCommon Stock · Non-derivative | 94,578A | 47.58 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: | M Exercise / conversionCommon Stock · Non-derivative | 90,726A | 44.65 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: | M Exercise / conversionCommon Stock · Non-derivative | 34,608A | 45.5 | Direct | Form 4 ↗0001535491-26-000007 |
| 2026-11-10Filed 2026-11-12 | Khalaf MichelDirector · Officer · President & CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: | M Exercise / conversionCommon Stock · Non-derivative | 28,817A | 46.85 | Direct | Form 4 ↗0001535491-26-000007 |
Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.